- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00270153
The Use of ACE Inhibitors in the Early Renal Post-transplant Period
Chronic allograft nephropathy (CAN) is the leading cause of longterm renal transplant loss. Angiotensin-II may play a role in the development and progression of CAN. Angiotensin converting enzyme inhibitors (ACEI) comprise a drug class that inhibit the effects of angiotensin-II. However these drugs have been reported to cause elevated potassium and creatinine levels in some renal transplant patients. Yet, there are now several retrospective reports of long term benefits of improved renal function and graft survival in renal transplant recipients. There have been no reports of prospective randomized controlled trials of ACEI in renal transplant patients in the early post transplant period.
The purpose of the present study is to assess the safety of enalapril, a drug in the ACEI class, when started 1-3 month post transplant. This is a double-blinded, randomized control trial of enalapril vs. placebo in new renal transplant patients with serum creatinine values no higher than 2.5mg/dl and normal serum potassium levels. The study drug will be administered for 6 months. Patients will be monitored in the renal transplant clinic every 1-4 weeks according to routine protocol. Clinical end-points will be occurence of potassium >5.9mEQ/L or sustained increase in serum creatinine >30% from baseline.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States, 10467-2490
- Montefiore Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- New adult renal transplant recipients with good renal function defined as serum creatinine less than 2.6 mg/dl,
- Normal serum potassium levels,
- No contraindication to ACE inhibitor use
Exclusion Criteria:
- Renal transplant patients with persistent serum creatinine levels over 2.5 mg/dl
- Hyperkalemia with serum potassium levels over 5.5 mEQ/dl
- History of allergic reaction to ACE inhibitors or angiotensin receptor blockers
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
5mg enalapril-matching placebo daily for 6 months
|
Placebo Comparator: enalapril
|
5mg enalapril daily for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in serum creatinine levels assessed at 6 months
Time Frame: Baseline and 6 months
|
Creatinine is a waste product that comes from the normal wear and tear on muscles of the body.
It is excreted through the kidneys.
High serum creatinine levels in the blood indicate that the kidneys aren't functioning properly.
Increase in serum creatinine of 30% would be a safety concern and requires clinical management.
|
Baseline and 6 months
|
Changes in potassium levels assessed at 6 months
Time Frame: Baseline and 6 months
|
Potassium is a chemical that is critical to the function of nerve and muscle cells, including those in your heart.
Potassium levels must be kept within a very narrow concentration range.
High Potassium levels are a sign of worsening kidney function.
An occurence of serum potassium greater than 5.9 mEq/L is a safety concern and requires clinical management.
|
Baseline and 6 months
|
Decrease in estimated glomerular filtration rate (eGFR) assessed at 6 months
Time Frame: Baseline and 6 months.
|
eGFR is a number based on your blood test for creatinine, a waste product in your blood.It tells how well your kidneys are working.
A normal eGFR is 60 or more.
A 25 percent decrease in eGFR indicates that the kidneys may not be working well.
This is a safety concern and requires clinical management.
|
Baseline and 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cough due to drug intolerance assessed at 6 months
Time Frame: Baseline and 6 months
|
Cough experienced because of inability to tolerate the adverse effects of the medication
|
Baseline and 6 months
|
abdominal pain due to drug intolerance assessed at 6 months
Time Frame: Baseline and 6 months
|
Abdominal pain experienced because of inability to tolerate the adverse effects of the medication
|
Baseline and 6 months
|
Erythrocytosis assessed at 6 months
Time Frame: Baseline and 6 months
|
Erythrocytosis is a condition in which your body makes too many red blood cells (RBCs).
Too many red blood cells can make your blood thicker than normal and lead to blood clots and other complications.
|
Baseline and 6 months
|
Leukopenia assessed at 6 months
Time Frame: Baseline and 6 months
|
Leukopenia is a decrease in the number of white blood cells found in the blood, which places individuals at increased risk of infection.
|
Baseline and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maria Coco, MD, Montefiore Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 03-12-311
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplant
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
Queen Mary University of LondonRecruitingImmunosuppression | Renal Transplant Rejection | Renal Transplant Failure | Renal Transplant InfectionUnited Kingdom
-
PfizerCompletedRenal Transplant | Graft Rejection | Kidney Transplant | Renal Allograft RecipientsUnited States, Australia, Germany, Italy, Spain, Brazil, Argentina
-
Ha Young OhBaxter Healthcare CorporationUnknownAcute Rejection of Renal Transplant | Delayed Function of Renal Transplant | Primary Nonfunction of Renal TransplantKorea, Republic of
-
Alp SenerNot yet recruitingRenal Transplant | Kidney Transplant
-
National Taiwan University HospitalUnknownRenal Transplant | Liver TransplantTaiwan
-
National Institute of Allergy and Infectious Diseases...University of PittsburghRecruitingKidney Transplant | Renal Transplant RecipientsUnited States
-
Liverpool University Hospitals NHS Foundation TrustKidney Research United KingdomNot yet recruitingFrailty | Kidney Transplant Rejection | Renal Transplant | Diagnosis | Kidney Transplant; Complications | Kidney Transplant | Renal Transplant Failure | Transplant DysfunctionUnited Kingdom
-
Jeffrey Veale, MDOneLegacy FoundationRecruitingTolerance | Renal Transplant Rejection | Kidney TransplantUnited States
-
University of AarhusCompletedRenal Transplant Candidate for Right Kidney | Renal Transplant Candidate for Left KidneyDenmark
Clinical Trials on enalapril
-
Ethicare GmbHUnknownHeart Failure | Dilated Cardiomyopathy | Congenital Heart DiseaseAustria, United Kingdom, Netherlands, Serbia, Hungary
-
Ethicare GmbHUnknownHeart Failure | Dilated CardiomyopathyAustria, United Kingdom, Hungary, Netherlands, Serbia
-
Ethicare GmbHUnknownHeart Failure | Congenital Heart DiseaseAustria, United Kingdom, Hungary, Netherlands, Serbia
-
Boehringer IngelheimCompleted
-
Shenzhen Ausa Pharmed Co.,LtdAnhui Medical UniversityCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Heart Failure | Coronary Disease | Hypertension
-
National Center for Research Resources (NCRR)Stanford UniversityCompletedIGA Glomerulonephritis
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Failure | Myocardial Diseases
-
Herlev HospitalUnknownCardiovascular Diseases | Kidney Failure, ChronicDenmark
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of EnalaprilJapan